The conversation about artificial intelligence in healthcare has developed a specific quality over the last several years — a quality of enthusiasm that is occasionally disconnected from a rigorous examination of what AI in healthcare actually requires to work. The models are improving. The clinical applications are multiplying. The investment is substantial. And underneath all of it sits a problem that receives a fraction of the attention it deserves: the data that AI systems need to function in healthcare is fragmented, inconsistent, inaccessible, and in many cases, effectively unusable.
Healthcare generates an extraordinary volume of data. Patient records, lab results, prescription histories, imaging, wearable data, clinical trial outcomes — the data exists, in enormous quantities, distributed across thousands of disconnected systems that were not designed to communicate with each other. A hospital system cannot easily access the records from the specialist network three miles away. A clinical trial coordinator cannot efficiently aggregate patient data from multiple sites without a manual reconciliation process that takes weeks. A patient cannot reliably access their own complete health history without navigating a bureaucratic obstacle course that has no equivalent in any other consumer context.
This is the infrastructure problem. And it is responsible for an estimated two hundred to three hundred billion dollars in annual healthcare inefficiency in the United States alone — not as a theoretical estimate, but as a measurable cost embedded in duplicated tests, delayed diagnoses, medication errors, and clinical trial timelines that are far longer and more expensive than they need to be.
The AI applications being built on top of fragmented healthcare data are limited by the quality of their inputs in ways that are not always visible from the output. A clinical decision support tool trained on incomplete patient histories makes recommendations that are bounded by what it can see. A chronic disease management platform that cannot access the patient's full medication history cannot optimize effectively. A drug discovery process that relies on manually aggregated clinical trial data is slower and more expensive than one built on unified, structured, accessible data infrastructure.
The companies building AI applications in healthcare are, in many cases, building on top of a foundation that limits what their applications can achieve. The constraint is not the model. It is the data layer beneath it. And the data layer will not improve through the accumulation of better models — it will improve through the construction of infrastructure that makes healthcare data secure, unified, and genuinely usable at the point where clinical and operational decisions are being made.
This is what Patientory is building. Enterprise health data infrastructure that takes fragmented patient data and transforms it into secure, patient-controlled health wallets — giving individuals ownership of their health information and giving healthcare systems, insurers, and researchers access to data that is structured, consented, and actionable in ways that the current fragmented landscape cannot support.
The abstract case for health data infrastructure is straightforward. What makes Patientory a compelling investment is the evidence that the infrastructure is producing measurable outcomes rather than remaining theoretical.
A twenty-two percent improvement in medication adherence in populations using the platform. An eighteen percent reduction in risk markers. A thirty percent acceleration in clinical trial data aggregation. These are not projections — they are results from active pilots with insurers, government entities, and clinical research organizations across multiple markets. The infrastructure is working, and the outcomes it is producing are the kind that healthcare systems are willing to pay for because the cost savings and clinical improvements they represent are substantial and measurable.
The global expansion pipeline — across the United States, Korea, the European Union, the United Kingdom, and the UAE — reflects a market reality that is not unique to any single healthcare system. Fragmented health data is a universal problem. The infrastructure that solves it is globally deployable. And the regulatory environments in each of those markets, while different in their specifics, share the common thread of increasing pressure on healthcare systems to reduce costs and improve outcomes — precisely the problem that unified data infrastructure addresses.
The most important thing about building the data layer correctly is what it enables downstream. A healthcare system with unified, patient-controlled data infrastructure is not just more efficient operationally — it is more capable clinically. The AI applications built on top of that infrastructure can see what they need to see. The clinical decisions supported by that infrastructure are informed by complete rather than partial information. The research conducted on that infrastructure produces insights faster and at lower cost.
The companies that win in AI over the next decade will not all be the ones with the best models. A significant number of them will be the ones that built the data infrastructure that made the best models possible — in healthcare and in every other domain where data is the binding constraint on what AI can accomplish.
Patientory is building that infrastructure for healthcare. The outcomes are already visible. The scale of what becomes possible as the infrastructure matures is the investment thesis.
#HealthTech #AI #DataInfrastructure #PortfolioSpotlight #VentureCapital #Opinion
Subscribe to our newsletter to stay up to date with the latest news.
